[go: up one dir, main page]

FR11C0027I1 - Virus de l'influenza recombinants pour vaccins et traitement genetique - Google Patents

Virus de l'influenza recombinants pour vaccins et traitement genetique

Info

Publication number
FR11C0027I1
FR11C0027I1 FR11C0027C FR11C0027I1 FR 11C0027 I1 FR11C0027 I1 FR 11C0027I1 FR 11C0027 C FR11C0027 C FR 11C0027C FR 11C0027 I1 FR11C0027 I1 FR 11C0027I1
Authority
FR
France
Prior art keywords
vaccines
influenza viruses
recombinant influenza
genetic treatment
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26826080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0027(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of FR11C0027I1 publication Critical patent/FR11C0027I1/fr
Application granted granted Critical
Publication of FR11C0027I2 publication Critical patent/FR11C0027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FR11C0027C 1999-04-06 2011-07-26 Virus de l'influenza recombinants pour vaccins et traitement genetique Active FR11C0027I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12791299P 1999-04-06 1999-04-06
US13283999P 1999-05-06 1999-05-06
PCT/US2000/009021 WO2000060050A2 (fr) 1999-04-06 2000-04-05 Virus de l'influenza recombinants pour vaccins et traitement genetique

Publications (2)

Publication Number Publication Date
FR11C0027I1 true FR11C0027I1 (fr) 2011-08-26
FR11C0027I2 FR11C0027I2 (fr) 2021-12-31

Family

ID=26826080

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0027C Active FR11C0027I2 (fr) 1999-04-06 2011-07-26 Virus de l'influenza recombinants pour vaccins et traitement genetique

Country Status (19)

Country Link
EP (4) EP2345716B1 (fr)
JP (3) JP5543048B2 (fr)
KR (1) KR100702275B1 (fr)
CN (2) CN101851636B (fr)
AT (2) ATE368729T1 (fr)
AU (1) AU4073300A (fr)
BR (1) BRPI0009580B8 (fr)
CA (2) CA2365526C (fr)
CY (2) CY1108520T1 (fr)
DE (6) DE122008000061I1 (fr)
DK (3) DK1820853T3 (fr)
ES (3) ES2373405T3 (fr)
FR (1) FR11C0027I2 (fr)
HK (1) HK1214298A1 (fr)
IL (2) IL145702A0 (fr)
MX (1) MXPA01010082A (fr)
NL (2) NL300365I2 (fr)
PT (2) PT1820853E (fr)
WO (1) WO2000060050A2 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP2345716B1 (fr) * 1999-04-06 2015-01-14 Wisconsin Alumni Research Foundation Virus de la grippe recombinant pour vaccins et thérapie génétique
GB9916794D0 (en) * 1999-07-16 1999-09-22 Isis Innovation In vitro virus reconstitution
DE122007000070I1 (de) * 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
DE60137345D1 (de) 2000-04-28 2009-02-26 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
EP1862550A1 (fr) * 2000-06-23 2007-12-05 Wyeth Holdings Corporation Ensemble de particules de virus du type de la grippe chimérique et sauvage (VLP)
EP1294892B1 (fr) * 2000-06-23 2007-10-17 Wyeth Holdings Corporation Assemblage sauvage-chimerique de particules virales de la grippe (vlp)
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
HUE050222T2 (hu) * 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Szignál influenzavírus-vektorok pakolására
CN103540613A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
US20050158342A1 (en) 2003-12-23 2005-07-21 Medimmune, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
JP5215561B2 (ja) * 2003-05-28 2013-06-19 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン及び遺伝子治療のための高力価組換えインフルエンザ・ウイルス
CA2816222A1 (fr) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Hemagglutinine du virus de la grippe et variantes de la neuraminidase
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
EP2530147B1 (fr) 2004-05-25 2014-09-10 MedImmune, LLC Hémagglutinine de la grippe et variantes de la neuraminidase
JP2008520248A (ja) 2004-11-19 2008-06-19 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション タンデム転写ユニットを有する組換えインフルエンザベクター
KR101316350B1 (ko) 2004-12-08 2013-10-15 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
AU2005318087B2 (en) 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
WO2007052058A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins influenza comprenant des combinaisons d'adjuvants particulaires et d'immunopotentiateurs
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
HUE049580T2 (hu) 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
WO2007126810A2 (fr) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation Virus de la grippe recombinants à haut titre pour vaccins
US20090017444A1 (en) * 2006-06-09 2009-01-15 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
JP2010500034A (ja) 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
EP4585610A3 (fr) 2006-09-11 2025-09-24 Seqirus UK Limited Fabrication de vaccins contre le virus de la grippe sans utiliser d'oeufs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
US8597661B2 (en) 2007-05-04 2013-12-03 Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
WO2008156778A2 (fr) 2007-06-18 2008-12-24 Tokiko Watanabe Virus mutants de protéine m2 de la grippe comme vaccins vivants atténués contre la grippe
JP5666905B2 (ja) 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
EP2045323A1 (fr) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Constructions linéaires d'expression pour la production de particules de virus influenza
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
CN101497877B (zh) * 2008-01-28 2012-09-05 河北摩百生物科技有限公司 流感全病毒减活疫苗重组体、其构建方法及应用
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
BRPI0915487A2 (pt) 2008-07-11 2017-06-27 Medimmune Inc hemaglutina de nfluenza e variantes de neuraminidase
CA2734643A1 (fr) 2008-08-18 2010-02-25 The Kitasato Institute Antigene du virus de la grippe aviaire et procede d'immunisation de rappel pour un vaccin contre la grippe aviaire en combinaison avec un adjuvant muqueux qui est efficace par administration orale
EP2233568A1 (fr) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Nouveau procédé pour la génération de virus d'ARN
EP3173097A3 (fr) 2009-02-10 2017-07-12 Seqirus UK Limited Vaccins contre la grippe dotés de quantités réduites de squalène
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP2396031A1 (fr) 2009-02-10 2011-12-21 Novartis AG Vaccins contre l'influenza possédant des quantités accrues d'antigène h3
WO2010093537A2 (fr) 2009-02-12 2010-08-19 Medimmune, Llc Hémagglutinine du virus de la grippe et variants de la neuraminidase
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
WO2011056591A1 (fr) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation Virus recombinants de la grippe de titre élevé à réplication améliorée dans les cellules vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN103237890A (zh) 2010-06-02 2013-08-07 巴克斯特保健股份有限公司 用于产生rna 病毒的方法和辅助病毒
CN102220293B (zh) * 2011-05-26 2012-12-19 中国农业科学院上海兽医研究所 犬流感重组病毒及其制备方法和应用
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
US20140302077A1 (en) 2011-09-02 2014-10-09 Westfaelische Wilhelms-Universitaet Munester Live attenuated influenza virus
WO2013057715A1 (fr) 2011-10-20 2013-04-25 Novartis Ag Vaccins avec adjuvant contre le virus grippal b pour primo-vaccination pédiatrique
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2015009743A1 (fr) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation Virus influenza recombinés à titre élevé avec augmentation de la réplication dans les oeufs ou les cellules de la lignée vero ou mdck
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CN107921117B (zh) * 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
JP2018530314A (ja) 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
WO2017143236A1 (fr) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Réplication améliorée du virus de la grippe b pour l'élaboration de vaccin
CA3074202A1 (fr) * 2017-08-28 2019-03-07 Wisconsin Alumni Research Foundation Nanocapsules pour l'administration de ribonucleoproteines
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CN107964035B (zh) * 2017-12-06 2020-07-24 中国科学院微生物研究所 一种用于流感病毒的有限复制型黏膜免疫疫苗
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
EP3921413A1 (fr) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Lignée cellulaire humanisée
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (fr) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Virus de la grippe multivalents recombinants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5658772A (en) 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
EP0704533A1 (fr) * 1994-09-30 1996-04-03 Bayer Ag Virus atténué pour la vaccination, méthode pour sa fabrication et compositions pharmaceutiques le contenant
WO1996010633A1 (fr) * 1994-09-30 1996-04-11 Aviron Virus chimere de la grippe et procede d'electroporation
CN1200675A (zh) * 1995-10-20 1998-12-02 耶路撒冷希伯来语大学依苏姆研究开发公司 流感疫苗
US5994526A (en) * 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
EP1035209A1 (fr) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Virus influenza recombinants stables dépourvus de virus auxiliaire
EP2345716B1 (fr) * 1999-04-06 2015-01-14 Wisconsin Alumni Research Foundation Virus de la grippe recombinant pour vaccins et thérapie génétique

Also Published As

Publication number Publication date
CN101851636A (zh) 2010-10-06
CA2365526C (fr) 2016-07-05
IL145702A (en) 2010-04-15
WO2000060050A2 (fr) 2000-10-12
BR0009580A (pt) 2002-01-02
IL145702A0 (en) 2002-07-25
CN101851636B (zh) 2015-11-25
CA2928263A1 (fr) 2000-10-12
DE60035778D1 (de) 2007-09-13
PT1820853E (pt) 2012-01-03
JP5775351B2 (ja) 2015-09-09
DE122008000035I1 (de) 2009-05-20
MXPA01010082A (es) 2002-04-24
AU4073300A (en) 2000-10-23
NL300364I2 (nl) 2017-08-03
JP2011182797A (ja) 2011-09-22
PT1185615E (pt) 2007-10-04
BR0009580B1 (pt) 2014-11-25
HK1214298A1 (en) 2016-07-22
ATE525461T1 (de) 2011-10-15
FR11C0027I2 (fr) 2021-12-31
EP2345716B1 (fr) 2015-01-14
NL300364I1 (nl) 2009-01-05
EP1820853A3 (fr) 2007-10-03
EP1820853B1 (fr) 2011-09-21
EP1185615A2 (fr) 2002-03-13
DE122008000014I1 (de) 2011-12-01
JP2003528570A (ja) 2003-09-30
EP1185615B1 (fr) 2007-08-01
CY1112140T1 (el) 2015-11-04
JP5543048B2 (ja) 2014-07-09
ES2373405T3 (es) 2012-02-03
JP6224645B2 (ja) 2017-11-01
JP2015119735A (ja) 2015-07-02
EP2345716A1 (fr) 2011-07-20
CN1350578B (zh) 2010-05-12
KR100702275B1 (ko) 2007-03-30
DE122008000061I1 (de) 2009-02-12
HK1148778A1 (zh) 2011-09-16
DK1820853T3 (da) 2011-12-19
ES2290024T3 (es) 2008-02-16
KR20010113044A (ko) 2001-12-24
WO2000060050A3 (fr) 2001-01-18
DE122008000058I1 (de) 2009-05-07
EP2910629A1 (fr) 2015-08-26
CA2365526A1 (fr) 2000-10-12
DE60035778T2 (de) 2008-04-30
EP1820853A2 (fr) 2007-08-22
EP2910629B1 (fr) 2018-09-19
NL300365I1 (nl) 2009-01-05
CN1350578A (zh) 2002-05-22
DK1185615T3 (da) 2007-11-05
ATE368729T1 (de) 2007-08-15
CY1108520T1 (el) 2014-04-09
DE122011100037I1 (de) 2012-03-22
NL300365I2 (nl) 2017-08-03
BRPI0009580B8 (pt) 2021-05-25
DK2345716T3 (en) 2015-02-09
ES2533622T3 (es) 2015-04-13

Similar Documents

Publication Publication Date Title
FR11C0027I2 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
EA200201279A1 (ru) Способы и композиции для лечения вирусного гепатита c
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
BG102712A (en) Mixture of recombinant vaccinia vectors as polyenv-vaccines against hiv
EP1383931A4 (fr) Vaccins d'acide nucleique pour la prevention d'infection a flavivirus
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ATE395078T1 (de) Impfstoff zur vorbeugung bzw. behandlung der hepatitis c
DE60024259D1 (de) Trennung eines humanen retrovirus
WO2003017943A3 (fr) Compositions therapeutiques et methodes de traitement d'infections virales
DK1339737T3 (da) Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
FI964784A0 (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
ATE322541T1 (de) Pestivirus mutanten und dessen enthaltende impfstoffe
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
WO2002039116A3 (fr) Retrovirus isoles chez l'homme
WO2000018430A3 (fr) Vaccins a virus actif destines a la protection de primates contre des infections et maladies dues au vih-1
WANG et al. The pilot study on mutations of HIV-1 envelop V3 loop in AIDS patients in Shenzhen
WO2000024876A3 (fr) Nouveau retrovirus isole chez l'homme